Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
TEL AVIV, Israel, Sept. 07, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.
Fredric Price, Executive Chairman, will provide an overview of the Company's business during the live presentation on Monday, September 12 at 2:10 PM and will be accompanied by Warren Wasiewski, MD, Chief Medical Officer and Chaime Orlev, who has recently joined Bioblast as Chief Financial Officer.
Event: 18th Annual Rodman & Renshaw Global Investment Conference
Date: September 12, 2016
Time: 2:10 PM
Location: Kennedy II, 4th floor, Lotte New York Palace Hotel in New York City
About Bioblast Pharma
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases with a lead drug candidate, trehalose 90mg/mL solution, in Phase 2 development. Bioblast was founded in 2012 and is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit our website, www.bioblastpharma.com, the content of which is not incorporated herein by reference.
INVESTOR CONTACT: Matthew P. Duffy Managing Director LifeSci Advisors, LLC Telephone: 212-915-0685
